Table of Contents
H2 Blockers in the Treatment of Gastric Hypersecretory Disorders: Case Examples
Gastric hypersecretory disorders, such as Zollinger-Ellison syndrome and severe peptic ulcer disease, involve excessive secretion of gastric acid. Managing these conditions often requires medications that reduce acid production, with H2 blockers playing a crucial role.
Understanding H2 Blockers
H2 blockers, also known as histamine H2 receptor antagonists, inhibit the action of histamine on H2 receptors in the stomach lining. This results in decreased secretion of gastric acid, alleviating symptoms and promoting healing of ulcers.
Common H2 Blockers
- Ranitidine (withdrawn in some markets)
- Famotidine
- Cimetidine
- Nizatidine
Famotidine is currently one of the most widely used due to its efficacy and safety profile.
Case Example 1: Zollinger-Ellison Syndrome
A 45-year-old male presented with severe abdominal pain, diarrhea, and multiple gastric ulcers. Elevated fasting serum gastrin levels suggested Zollinger-Ellison syndrome, caused by a gastrin-secreting tumor.
The patient was started on high-dose famotidine, which significantly reduced gastric acid secretion. This treatment alleviated symptoms and facilitated ulcer healing. Surgical removal of the tumor was planned subsequently.
Case Example 2: Severe Peptic Ulcer Disease
A 60-year-old woman with a history of recurrent peptic ulcers was admitted with bleeding ulcers confirmed via endoscopy. She was prescribed high-dose cimetidine to control acid secretion.
Her symptoms improved, and follow-up endoscopy showed healing of the ulcers. The medication was continued to prevent recurrence, along with eradication therapy for Helicobacter pylori infection.
Advantages and Limitations of H2 Blockers
H2 blockers are effective, well-tolerated, and easy to administer. However, they may develop tachyphylaxis over time, reducing their effectiveness. In some cases, they are less potent than proton pump inhibitors (PPIs).
Conclusion
H2 blockers remain a valuable option in managing gastric hypersecretory disorders, especially in cases where PPIs are contraindicated or insufficient. Case examples highlight their role in symptom control, ulcer healing, and improving patient outcomes.